NA Cardiac Safety Services Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-24
- Report ID: 143373
- Pages: 225
-
Format:
Short Description
North America Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029
Market Definition:
Cardiac safety services generally help support and design clinical trials and other research needed to monitor heart safety. The demand for cardiac safety services market has been increased in both developed well as in developing countries and the reason behind this is the increasing number of clinical trials and product launch. The cardiac safety services market is growing due to introduction of innovative products, increasing in technological products and rising disposable income. The market will grow in forecasted period due to exploration of emerging markets, strategic initiatives by market players, increasing healthcare expenditure.
Market Segmentation:
The cardiac safety services market is categorized into four notable segment which is services, type, phase and end user.
On the basis of services, the cardiac safety services market is segmented into ECG/Holter measurements, blood pressure measurements, in vitro cardiac safety assessment services, cardiovascular imaging, real-time telemetry monitoring, central over-read of ECGS, non-invasive cardiac imaging, physiologic stress testing, thorough QT studies, TQT and exposure response modeling, platelet aggregation and other services.
On the basis of phases, the cardiac safety services market is segmented into phase 1, phase 2 and phase 3. In 2022, phase 1 is expected to dominate the global cardiac safety services market with the increasing new drug development and rising strategic initiatives by major market players.
On the basis of type, the cardiac safety services market is segmented into integrated services and standalone services. In 2022, integrated services is expected to dominate the global cardiac safety services market with the increasing advanced technology and rising healthcare expenditure.
On the basis of end user, the cardiac safety services market is segmented pharmaceuticals & biopharmaceuticals companies, contract research organizations and academic and research institute. In 2022, hospital is expected to dominate the global cardiac safety services market with the increasing number of patients and surgeries.
Market Players
The key market players for North America cardiac safety services market are listed below:
Koninklijke Philips N.V.
Laboratory Corporation of America Holdings
IQVIA
Medpace
Ncardia
Certara
Eurofins Scientific
SGS SA
Banook
Celerion
PhysioStim
Shanghai Medicilon Inc
Clario
PPD Inc
TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF NORTH AMERICA CARDIAC SAFETY SERVICES MARKET 26
1.4 LIMITATIONS 27
1.5 MARKETS COVERED 28
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 CURRENCY AND PRICING 32
2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
2.6 MULTIVARIATE MODELLING 36
2.7 SERVICES LIFELINE CURVE 36
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.9 DBMR MARKET POSITION GRID 38
2.10 MARKET END USER GRID 40
2.11 VENDOR SHARE ANALYSIS 41
2.12 SECONDARY SOURCES 42
2.13 ASSUMPTIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 46
4.1 PORTERS FIVE FORCES 47
4.2 PESTEL ANALYSIS 48
5 EPIDEMIOLOGY 49
5.1 INCIDENCE OF ALL BY GENDER 49
5.2 TREATMENT RATE 50
5.3 MORTALITY RATE 50
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 51
6 INDUSTRY INSIGHT 52
6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 52
6.2 PATENT ANALYSIS 53
6.3 PATENT FLOW DIAGRAM 54
6.4 KEY PATIENT ENROLLMENT STRATEGIES 54
6.5 PRICING STRATEGY 57
7 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: REGULATIONS 58
8 MARKET OVERVIEW 61
8.1 DRIVERS 63
8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS 63
8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING 63
8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 64
8.1.4 INCREASE IN R&D ACTIVITIES 64
8.2 RESTRAINTS 65
8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION 65
8.2.2 STRICT REGULATORY 65
8.3 OPPORTUNITIES: 66
8.3.1 INCREASE IN NEW DRUG DEVELOPMENT 66
8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES 67
8.4 CHALLENGES 67
8.4.1 TIME-CONSUMING PROCEDURE 67
8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION 68
9 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES 69
9.1 OVERVIEW 70
9.2 ECG/HOLTER MEASUREMENTS 74
9.3 BLOOD PRESSURE MEASUREMENTS 74
9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES 75
9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS 76
9.4.1.1 1 CONCENTRATIONS 76
9.4.1.2 4 CONCENTRATIONS 76
9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) 77
9.4.2.1 3 CONCENTRATIONS 77
9.4.2.2 5 CONCENTRATIONS 77
9.4.3 IN VITRO HERG ASSAY 77
9.4.4 OTHERS 77
9.5 CARDIOVASCULAR IMAGING 77
9.6 REAL TIME TELEMETRY MONITORING 78
9.7 CENTRAL OVER-READ OF ECGS 79
9.8 NON-INVASIVE CARDIAC IMAGING 79
9.9 PHYSIOLOGIC STRESS TESTING 80
9.10 THOROUGH QT STUDIES 81
9.11 TQT AND EXPOSURE RESPONSE MODELLING 81
9.12 PLATELET AGGREGATION 82
9.13 OTHERS 83
10 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY PHASE 84
10.1 OVERVIEW 85
10.2 PHASE I 88
10.3 PHASE II 88
10.4 PHASE III 89
11 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY TYPE 90
11.1 OVERVIEW 91
11.2 INTEGRATED SERVICES 94
11.3 STANDALONE SERVICES 95
12 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY END USER 96
12.1 OVERVIEW 97
12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES 100
12.3 CONTRACT RESEARCH ORGANIZATIONS 100
12.4 ACADEMIC AND RESEARCH INSTITUTE 101
13 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET, BY REGION 102
13.1 NORTH AMERICA 103
13.1.1 U.S. 111
13.1.2 CANADA 114
13.1.3 MEXICO 117
14 NORTH AMERICA CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE 120
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 120
15 COMPANY PROFILE 121
15.1 EUROFINS SCIENTIFIC 121
15.1.1 COMPANY SNAPSHOT 121
15.1.2 REVENUE ANALYSIS 122
15.1.3 COMPANY SHARE ANALYSIS 122
15.1.4 PRODUCT PORTFOLIO 122
15.1.5 RECENT DEVELOPMENTS 123
15.1.5.1 AGREEMENTS 123
15.1.5.2 ACQUISITION 123
15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC) 124
15.2.1 COMPANY SNAPSHOT 124
15.2.2 REVENUE ANALYSIS 124
15.2.3 COMPANY SHARE ANALYSIS 125
15.2.4 PRODUCT PORTFOLIO 125
15.2.5 RECENT DEVELOPMENT 125
15.2.5.1 INVESTMENT 125
15.3 KONINKLIJKE PHILIPS N.V. 126
15.3.1 COMPANY SNAPSHOT 126
15.3.2 REVENUE ANALYSIS 126
15.3.3 COMPANY SHARE ANALYSIS 127
15.3.4 PRODUCT PORTFOLIO 127
15.3.5 RECENT DEVELOPMENT 127
15.3.5.1 ACQUISITION 127
15.4 IQVIA 128
15.4.1 COMPANY SNAPSHOT 128
15.4.2 REVENUE ANALYSIS 128
15.4.3 COMPANY SHARE ANALYSIS 129
15.4.4 PRODUCT PORTFOLIO 129
15.4.5 RECENT DEVELOPMENTS 129
15.4.5.1 ACQUISITION 129
15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 130
15.5.1 COMPANY SNAPSHOT 130
15.5.2 REVENUE ANALYSIS 130
15.5.3 COMPANY SHARE ANALYSIS 131
15.5.4 PRODUCT PORTFOLIO 131
15.5.5 RECENT DEVELOPMENTS 131
15.5.5.1 NEW LABORATORY 131
15.5.5.2 ACQUISITION 131
15.6 BANOOK 132
15.6.1 COMPANY SNAPSHOT 132
15.6.2 PRODUCT PORTFOLIO 132
15.6.3 RECENT DEVELOPMENT 132
15.6.3.1 AGREEMENT 132
15.7 BIOTRIAL 133
15.7.1 COMPANY SNAPSHOT 133
15.7.2 PRODUCT PORTFOLIO 133
15.7.3 RECENT DEVELOPMENT 133
15.7.3.1 NEW CENTER OPENING 133
15.8 CELERION 134
15.8.1 COMPANY SNAPSHOT 134
15.8.2 PRODUCT PORTFOLIO 134
15.8.3 RECENT DEVELOPMENT 134
15.8.3.1 NEW CENTER OPENING 134
15.9 CERTARA 135
15.9.1 COMPANY SNAPSHOT 135
15.9.2 REVENUE ANALYSIS 135
15.9.3 PRODUCT PORTFOLIO 136
15.9.4 RECENT DEVELOPMENTS 136
15.9.4.1 CONTRACT 136
15.9.4.2 ACQUISITION 136
15.10 CLARIO 137
15.10.1 COMPANY SNAPSHOT 137
15.10.2 PRODUCT PORTFOLIO 137
15.10.3 RECENT DEVELOPMENT 137
15.10.3.1 PRODUCT EXPANSION 137
15.11 MEDPACE 138
15.11.1 COMPANY SNAPSHOT 138
15.11.2 REVENUE ANALYSIS 138
15.11.3 PRODUCT PORTFOLIO 139
15.11.4 RECENT DEVELOPMENTS 139
15.11.4.1 ACQUISITION 139
15.12 NCARDIA 140
15.12.1 COMPANY SNAPSHOT 140
15.12.2 PRODUCT PORTFOLIO 140
15.12.3 RECENT DEVELOPMENT 140
15.12.3.1 PARTNERSHIP 140
15.13 NEXEL CO., LTD 141
15.13.1 COMPANY SNAPSHOT 141
15.13.2 PRODUCT PORTFOLIO 141
15.13.3 RECENT DEVELOPMENTS 141
15.13.3.1 JOINT VENTURE 141
15.13.3.2 PARTNERSHIP 142
15.14 PHYSIOSTIM 143
15.14.1 COMPANY SNAPSHOT 143
15.14.2 PRODUCT PORTFOLIO 143
15.14.3 RECENT DEVELOPMENT 143
15.14.3.1 PARTNERSHIP 143
15.15 RICHMOND PHARMACOLOGY 144
15.15.1 COMPANY SNAPSHOT 144
15.15.2 PRODUCT PORTFOLIO 144
15.15.3 RECENT DEVELOPMENT 144
15.15.3.1 EVENT 144
15.16 SGS SA 145
15.16.1 COMPANY SNAPSHOT 145
15.16.2 REVENUE ANALYSIS 145
15.16.3 PRODUCT PORTFOLIO 146
15.16.4 RECENT DEVELOPMENT 146
15.16.4.1 ACQUISITION 146
15.17 SHANGHAI MEDICILON INC. 147
15.17.1 COMPANY SNAPSHOT 147
15.17.2 PRODUCT PORTFOLIO 147
15.17.3 RECENT DEVELOPMENTS 147
15.17.3.1 PARTNERSHIP 147
15.17.3.2 PARTNERSHIP 148
16 QUESTIONNAIRE 149
17 RELATED REPORTS 151
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
